dc.contributor.author
Jacobs, Miriam N.
dc.contributor.author
Hoffmann, Sebastian
dc.contributor.author
Hollnagel, Heli M.
dc.contributor.author
Kern, Petra
dc.contributor.author
Kolle, Susanne N.
dc.contributor.author
Natsch, Andreas
dc.contributor.author
Landsiedel, Robert
dc.date.accessioned
2024-06-25T07:57:37Z
dc.date.available
2024-06-25T07:57:37Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/43461
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-43178
dc.description.abstract
The ongoing transition from chemical hazard and risk assessment based on animal studies to assessment relying mostly on non-animal data, requires a multitude of novel experimental methods, and this means that guidance on the validation and standardisation of test methods intended for international applicability and acceptance, needs to be updated. These so-called new approach methodologies (NAMs) must be applicable to the chemical regulatory domain and provide reliable data which are relevant to hazard and risk assessment. Confidence in and use of NAMs will depend on their reliability and relevance, and both are thoroughly assessed by validation. Validation is, however, a time- and resource-demanding process. As updates on validation guidance are conducted, the valuable components must be kept: Reliable data are and will remain fundamental. In 2016, the scientific community was made aware of the general crisis in scientific reproducibility—validated methods must not fall into this. In this commentary, we emphasize the central importance of ring trials in the validation of experimental methods. Ring trials are sometimes considered to be a major hold-up with little value added to the validation. Here, we clarify that ring trials are indispensable to demonstrate the robustness and reproducibility of a new method. Further, that methods do fail in method transfer and ring trials due to different stumbling blocks, but these provide learnings to ensure the robustness of new methods. At the same time, we identify what it would take to perform ring trials more efficiently, and how ring trials fit into the much-needed update to the guidance on the validation of NAMs.
en
dc.format.extent
17 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
OECD Test Guidelines
en
dc.subject.ddc
500 Naturwissenschaften und Mathematik::540 Chemie::540 Chemie und zugeordnete Wissenschaften
dc.title
Avoiding a reproducibility crisis in regulatory toxicology—on the fundamental role of ring trials
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.doi
10.1007/s00204-024-03736-z
dcterms.bibliographicCitation.journaltitle
Archives of Toxicology
dcterms.bibliographicCitation.number
7
dcterms.bibliographicCitation.pagestart
2047
dcterms.bibliographicCitation.pageend
2063
dcterms.bibliographicCitation.volume
98
dcterms.bibliographicCitation.url
https://doi.org/10.1007/s00204-024-03736-z
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Pharmazie
refubium.funding
Springer Nature DEAL
refubium.note.author
Die Publikation wurde aus Open Access Publikationsgeldern der Freien Universität Berlin gefördert.
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1432-0738